Home Online Features AKAGERA Medicines, Inc. announces the completion of the first cohort in the IV AKG-100 phase 1 study for the treatment of pulmonary tuberculosis.
AKAGERA Medicines, Inc. announces the completion of the first cohort in the IV AKG-100 phase 1 study for the treatment of pulmonary tuberculosis.
Hand-out
Press Releases
Akagera Medicines Inc  
April 1, 2025

AKAGERA Medicines, Inc. announces the completion of the first cohort in the IV AKG-100 phase 1 study for the treatment of pulmonary tuberculosis.

KIGALI, Rwanda and WALTHAM, Mass., April 1, 2025 /PRNewswire/ -- AKAGERA Medicines, Inc. is a biotech company focused on the discovery and development of novel lipid nanoparticle formulations of antibacterial

logo salamanca press

Salamanca Press

email salamanca press
Local & Social